Antigenics (ANTI) Stock Price

Antigenics Price

NYSE·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Over the last 9 years Antigenics grew revenue by 62.8% annually, reaching 3.22 M USD. For Antigenics, the net margin of -557.8% is down versus -300.7% a few years ago.

Antigenics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Antigenics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Antigenics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Antigenics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Antigenics Stock Price History
DateAntigenics Price
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Antigenics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 1993
50,000.00 USD
-6.32 M USD
-6.23 M USD
Jan 1, 1994
200,000.00 USD
-9.39 M USD
-9.05 M USD
Jan 1, 1995
1.25 M USD
-9.31 M USD
-17.43 M USD
Jan 1, 1996
2.67 M USD
-9.31 M USD
-8.03 M USD
Jan 1, 1997
841,000.00 USD
-15.79 M USD
-16.99 M USD
Jan 1, 1998
6.74 M USD
-19.41 M USD
-18.23 M USD
Jan 1, 1999
11.05 M USD
-15.09 M USD
-14.09 M USD
Jan 1, 2000
3.22 M USD
-16.63 M USD
-17.96 M USD

Antigenics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 4:41 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
19901991199219931994199519961997199819992000
–––––1.002.00–6.0011.003.00
––––––100.00––83.33-72.73
-1.00-2.00-4.00-6.00-9.00-9.00-9.00-15.00-19.00-15.00-16.00
–––––-900.00-450.00–-316.67-136.36-533.33
-1.00-2.00-4.00-6.00-9.00-17.00-8.00-16.00-18.00-14.00-17.00
–100.00100.0050.0050.0088.89-52.94100.0012.50-22.2221.43
2.412.512.983.605.156.4913.0514.9015.5721.7324.85
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Antigenics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Antigenics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Antigenics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Antigenics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Antigenics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Antigenics stock margins

The Antigenics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Antigenics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Antigenics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 1993
0.00 %
-12,640.00 %
-12,460.00 %
Jan 1, 1994
0.00 %
-4,695.00 %
-4,525.00 %
Jan 1, 1995
0.00 %
-746.31 %
-1,396.55 %
Jan 1, 1996
0.00 %
-348.58 %
-300.75 %
Jan 1, 1997
0.00 %
-1,877.88 %
-2,020.33 %
Jan 1, 1998
0.00 %
-288.11 %
-270.61 %
Jan 1, 1999
0.00 %
-136.57 %
-127.52 %
Jan 1, 2000
0.00 %
-516.71 %
-557.84 %

Antigenics Stock Revenue, EBIT, Earnings per Share

The Antigenics earnings per share therefore indicates how much revenue Antigenics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 1993
0.01 USD
-1.76 USD
-1.73 USD
Jan 1, 1994
0.04 USD
-1.82 USD
-1.76 USD
Jan 1, 1995
0.19 USD
-1.44 USD
-2.69 USD
Jan 1, 1996
0.20 USD
-0.71 USD
-0.62 USD
Jan 1, 1997
0.06 USD
-1.06 USD
-1.14 USD
Jan 1, 1998
0.43 USD
-1.25 USD
-1.17 USD
Jan 1, 1999
0.51 USD
-0.69 USD
-0.65 USD
Jan 1, 2000
0.13 USD
-0.67 USD
-0.72 USD

Antigenics business model & stock analysis

Antigenics Inc, now Agenus Inc, is a biotechnology company specializing in the research and development of innovative therapies for cancer and infectious diseases. The company is headquartered in Lexington, Massachusetts. The history of Antigenics begins in the late 1980s when the founder, Garo Armen, developed a method for identifying DNA sequences that encode specific proteins. The approach was based on the isolation of lentiviral vectors from human cells, which were then used to transfer the DNA sequences to other cells. This method allowed Antigenics to identify a variety of tumor-specific antigens (TSA) that could serve as potential targets for immunotherapies. In the 1990s, Antigenics focused on developing anti-tumor vaccines based on TSA. The first product was Oncophage, a vaccine made from individual TSA peptides isolated from the patient's tumor cells. Oncophage was tested in Phase II clinical trials in patients with various forms of cancer, including melanoma, renal cell carcinoma, and glioblastoma. Although the vaccine showed significant survival benefits in some studies, it was not approved in the United States. Today, Oncophage is used in Russia and India for the treatment of kidney cancer. In the late 2000s, Antigenics expanded its portfolio to include other immune-oncology approaches such as immune checkpoint protein CTLA-4 modulators, cytotoxic antibodies against cancer cells, and small molecules for immune activation. In 2014, the company was renamed Agenus Inc to reflect its expanded business model. Today, Agenus focuses on the development of immune combination therapies that combine various approaches to activate and modulate the immune system to achieve synergistic effects. The focus is on the use of immune checkpoint inhibitors that relieve T-cell inhibition, as well as the combination of vaccines and cytotoxic antibodies. Agenus' current products include immune checkpoint inhibitor CTLA-4 Ig, which is being tested in Phase III clinical trials for melanoma and lung cancer, and the QS-21 vaccine, which elicits a strong immune response and is used as an adjuvant for other vaccines for the treatment of infectious diseases. Agenus has various divisions, including a division for veterinary immunotherapies, which specializes in the development of vaccines and treatment methods for dogs and horses with cancer. Overall, Agenus has a rich history in the research and development of immunotherapies for the treatment of cancer and infectious diseases. Although the company has experienced setbacks in the past, it remains a key player in the field of immune-oncology and is expected to develop further groundbreaking therapies.

Antigenics SWOT Analysis

Strengths

Antigenics Inc possesses several strength factors that contribute to its success and competitive advantage.

  • Advanced technology and innovative research capabilities enable the development of cutting-edge medical products.
  • Strong intellectual property portfolio with patents and proprietary knowledge that provides exclusivity and safeguards against competition.
  • Experienced and knowledgeable team of experts with deep understanding of the biotechnology industry.

Weaknesses

Despite its strengths, Antigenics Inc also has some areas of weakness that may hinder its growth potential.

  • Relatively small size and limited financial resources compared to larger competitors, which can affect the company's ability to invest in research and development.
  • Dependency on a limited product portfolio, making the company vulnerable to market fluctuations or the failure of a single product.
  • Unpredictability of the biotechnology industry and regulatory hurdles that may delay product approvals or market launch timelines.

Opportunities

Antigenics Inc can leverage the following opportunities to expand its market presence and increase profitability.

  • Growing demand for biotechnology products globally, driven by an aging population and increasing chronic diseases.
  • Strategic partnerships with larger pharmaceutical companies that provide access to additional resources, distribution channels, and expertise.
  • Expansion into emerging markets with less competition and higher demand for biotech solutions.

Threats

Antigenics Inc should be aware of the following threats that could negatively impact its business operations and market position.

  • Intense competition from larger biotechnology companies, with greater financial capabilities and broader product portfolios.
  • Stringent regulatory requirements and approval processes that may lead to delays or failures in obtaining necessary certifications.
  • Potential technological advancements or breakthroughs by competitors that could render Antigenics Inc's products obsolete or less competitive.

Antigenics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Antigenics historical P/E ratio, EBIT multiple, and P/S ratio

Antigenics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Antigenics shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 1993
3.60 M Stocks
Jan 1, 1994
5.15 M Stocks
Jan 1, 1995
6.49 M Stocks
Jan 1, 1996
13.05 M Stocks
Jan 1, 1997
14.90 M Stocks
Jan 1, 1998
15.57 M Stocks
Jan 1, 1999
21.73 M Stocks
Jan 1, 2000
24.85 M Stocks
Price targets and forecasts for Antigenics are not yet available.

Antigenics Executives and Management Board

16 members · avg. age 60 · 13 % women

GC

DR. Geoffrey Cox (70)

Chairman of the Board, Chief Executive Officer · since 1997

476,498.00 USD

Management

DG

David Gordon (68)

Senior Vice President of Medical Affairs and Chief Medical Officer · since 1997

269,566.00 USD
AW

Dr. Anthony Williams (50)

Vice President, Medical Affairs · since 1999

261,136.00 USD
PT

Dr. Praveen Tyle (54)

Senior Vice President - Development and Operations, Chief Technology Officer · since 1998

218,937.00 USD
PC

Paul Cossum (53)

Vice President of Preclinical Development · since 1995

200,289.00 USD
WS

Dr. William Schary (57)

Vice President, Regulatory Affairs and Quality Assurance · since 1999

189,733.00 USD
JW

Janet Walter (42)

Vice President, Marketing and Business Development · since 1997

187,752.00 USD

Board of Directors

JB

Mr. James Butler (69)

Director · since 1997

–
PG

DR. Phyllis Gardner

Director · since 1998

–
PH

Mr. Paul Hobby (53)

Director · since 1999

–
GL

Gabriel Lopez-Berestein (58)

Director · since 1988

–
DM

Mr. David McLachlan (75)

Director · since 1999

–
MS

Mr. Martin Sutter (59)

Director · since 1997

–

Frequently asked questions about Antigenics

The business model of Antigenics Inc is focused on the research, development, and commercialization of innovative immunotherapeutic products for the treatment of various diseases. Antigenics Inc aims to leverage its expertise in antigen discovery, vaccine development, and immune-based therapies to bring about significant advancements in the field of healthcare. Through strategic partnerships and collaborations, the company aims to create and enhance value for its shareholders by successfully navigating the complex landscape of drug discovery and development. Antigenics Inc strives to address unmet medical needs and improve patient outcomes through the advancement of its therapeutic candidates.

Antigenics Inc primarily operates in the biotechnology and pharmaceutical industries.

The main competitors of Antigenics Inc in the market are other companies in the biotechnology industry such as Progenics Pharmaceuticals, Inc., Agenus Inc., and Celldex Therapeutics, Inc.

Antigenics Inc., now known as Agenus Inc., is a biotechnology company that focuses on the discovery, development, and commercialization of immunotherapies for the treatment of cancer and other diseases. Founded in 1994, Antigenics Inc. has a rich history of advancing innovative and personalized therapies that harness the power of the immune system. Over the years, the company has made significant contributions to the field of immuno-oncology and has built a strong portfolio of proprietary platforms and technologies. Antigenics Inc., now Agenus, continues to strive towards developing breakthrough treatments and improving patient outcomes in the fight against cancer.

Antigenics Inc has achieved several significant milestones over the years. One notable accomplishment is the FDA approval of their therapeutic vaccine, Oncophage, in 2010. This vaccine is designed to stimulate the body's immune response against cancer cells, offering a personalized treatment approach for each patient. Additionally, Antigenics Inc has successfully conducted clinical trials, demonstrated positive results, and developed a strong intellectual property portfolio. These achievements highlight the company's dedication to advancing immunotherapies and their commitment to improving patient outcomes in the field of oncology.

Antigenics Inc is primarily present in the United States.

Antigenics Inc represents a strong commitment to advancing innovative immunotherapies. With a focus on developing personalized treatment options, the company aims to address the unmet medical needs of patients. Antigenics Inc values scientific excellence and collaboration to drive groundbreaking research and development initiatives. By leveraging cutting-edge technologies and strategic partnerships, the company strives to improve patient outcomes and enhance quality of life. Emphasizing a patient-centric approach, Antigenics Inc is dedicated to providing hope and solutions for those affected by serious diseases.

Converted at the current exchange rate, the Antigenics share trades at 0.00 EUR (0.00 USD).

Antigenics Inc. is a biotechnology company specializing in the development and commercialization of immunotherapies for cancer and infectious diseases. The company is based in New York City and has offices in Europe and Asia. Antigenics Inc. specializes in the development of individualized immunotherapies for patients with advanced cancer. The company has a proprietary platform technology called A-Ox-HPV, which is based on the use of heat-inactivated Staphylococcus aureus (HISA). This technology allows for the development of personalized cancer vaccines for each patient, containing specific antigenic proteins of the tumor. Antigenics Inc. has conducted Phase II clinical trials for various types of cancer, including lung cancer, colorectal cancer, and prostate cancer. Antigenics Inc. has also developed a unique platform technology called QS-21, which can be used as an adjuvant for a variety of vaccines. QS-21 enhances the ability of the immune system to respond to a range of antigens. Antigenics has sublicensed this technology to other biotech and pharmaceutical companies. In addition to immunotherapies for cancer, Antigenics Inc. has also developed a range of products for the diagnosis and treatment of infectious diseases. The company has granted CEL-SCI Corporation exclusive license rights to use the HISA technology for the production of vaccines for infectious diseases such as Ebola and MERS-CoV. Antigenics Inc. also operates a business unit called AgroBioSciences, which specializes in the development of technologies for agriculture. This business unit uses the QS-21 technology to develop vaccines for livestock and plants. Antigenics Inc.'s business model is based on the development and commercialization of immunotherapies for cancer and infectious diseases, as well as the licensing of its platform technologies to other biotech and pharmaceutical companies. The company generates revenue from conducting clinical trials, selling products, and licensing its technologies. Antigenics Inc. is an innovative biotechnology company specializing in the development of individualized immunotherapies for cancer and infectious diseases. The company has a promising pipeline of immunotherapy candidates and platform technologies that allow it to maximize the potential of its products and have a significant impact on healthcare.

The revenue cannot currently be calculated for Antigenics.

The profit cannot currently be calculated for Antigenics.

The P/E ratio cannot be calculated for Antigenics at the moment.

The P/S cannot be calculated for Antigenics currently.

The Eulerpool Quality Score for Antigenics is 4/10.

The ISIN of Antigenics is US0370311013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Antigenics is 932075. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Antigenics is ANTI. The ticker symbol is used to trade Antigenics shares on the stock exchange.

Antigenics paid dividends every year for the past 0 years.

Antigenics is assigned to the '—' sector.

The dividends of Antigenics are distributed in USD.

All fundamentals and in-depth analysis of Antigenics

Our stock analysis for Antigenics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antigenics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Antigenics Stock
Antigenics Revenue→
Antigenics Stock
Antigenics Net Income→
Antigenics Stock
Antigenics P/E→
Antigenics Stock
Antigenics P/S→
Antigenics Stock
Antigenics EBIT→
Antigenics Stock
Antigenics Dividend→
Antigenics Stock
Antigenics Directors Dealings→
Antigenics Stock
Antigenics Stocks→
Antigenics Stock
Antigenics Market capitalization→
Antigenics Stock
Antigenics Debt→
Antigenics Stock
Antigenics Liabilities→
Antigenics Stock
Antigenics Equity→
Antigenics Stock
Antigenics AAQS→
Antigenics Stock
Antigenics Employees→
Antigenics Stock
Antigenics ROE→
Antigenics Stock
Antigenics ROA→
Antigenics Stock
Antigenics ROCE→
Antigenics Stock
Antigenics News→
Antigenics Stock
Antigenics Analyst Price Targets→

— Stocks

Antilia GroupAntiaging Quantum LivingAntipodes Global Investment CompanyAnteros MetalsAnTix HoldingsAntera Ventures IIAntler GoldAntarcticaAntler Hill MiningAnquiro VenturesAnugerah Spareparts Sejahtera PT TbkAnonymous Intelligence CompanyAll Stocks A–Z →